Abstract | BACKGROUND: AIM: METHODS: 36 patients with stable HF (65+/-13 years, 24 males/12 females, NYHA class II to IV, ejection fraction <40%, 13 with coronary disease, all treated with ACE inhibitors) were enrolled in this prospective, double-blind study and randomised to aspirin 325 mg/day or clopidogrel 75 mg/day for 14 days. BNP was determined at day 0 and day 14. RESULTS: 19 patients were randomised to aspirin and 17 to clopidogrel. Baseline characteristics were similar in both groups. BNP levels increased in the aspirin group from day 0 to day 14 (107+/-103 to 144+/-149 pg/ml, p=0.04) whereas clopidogrel had no effect (104+/-107 and 97+/-99 pg/ml respectively, p=0.61). CONCLUSION: This study demonstrates an adverse effect of aspirin 325 mg/day on BNP plasma levels in HF patients treated with ACE inhibitors. In contrast clopidogrel 75 mg/day had no effect.
|
Authors | Christophe Meune, Karim Wahbi, Yvonne Fulla, Alain Cohen-Solal, Denis Duboc, Isabelle Mahé, Guy Simoneau, Jean-François Bergmann, Simon Weber, Stéphane Mouly |
Journal | European journal of heart failure
(Eur J Heart Fail)
Vol. 9
Issue 2
Pg. 197-201
(Feb 2007)
ISSN: 1388-9842 [Print] England |
PMID | 16914369
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Angiotensin-Converting Enzyme Inhibitors
- Angiotensins
- Prostaglandins
- Natriuretic Peptide, Brain
- Clopidogrel
- Ticlopidine
- Aspirin
|
Topics |
- Aged
- Angiotensin-Converting Enzyme Inhibitors
(therapeutic use)
- Angiotensins
(drug effects)
- Aspirin
(adverse effects, pharmacology)
- Clopidogrel
- Female
- Heart Failure
(blood, drug therapy)
- Humans
- Male
- Middle Aged
- Natriuretic Peptide, Brain
(blood, drug effects)
- Prostaglandins
- Ticlopidine
(analogs & derivatives, pharmacology)
|